Liver Transplantation and Hepatic Resection can Achieve Cure for Hepatocellular Carcinoma

医学 肝细胞癌 肝移植 人口 统计显著性 米兰标准 内科学 移植 外科 胃肠病学 肿瘤科 环境卫生
作者
Antonio Daniele Pinna,Tian Yang,Vincenzo Mazzaferro,Luciano De Carlis,Jian Zhou,Sasan Roayaie,Feng Shen,Carlo Sposito,Matteo Cescon,Stefano Di Sandro,Yifeng He,Philip J. Johnson,Alessandro Cucchetti
出处
期刊:Annals of Surgery [Lippincott Williams & Wilkins]
卷期号:268 (5): 868-875 被引量:219
标识
DOI:10.1097/sla.0000000000002889
摘要

OBJECTIVE: The aim of this study was to estimate probabilities of achieving the statistical cure from hepatocellular carcinoma (HCC) with hepatic resection (HR) and liver transplantation (LT). BACKGROUND: Statistical cure occurs when the mortality of a specific population returns to values of that of general population. Resection and transplantation are considered potentially curative therapies for HCC, but their effect on the residual entire life-expectancy has never been investigated. METHODS: Data from 3286 HCC patients treated with LT (n = 1218) or HR (n = 2068) were used to estimate statistical cure. Disease-free survival (DFS) was the primary survival measure to estimate cure fractions through a nonmixture model. Overall survival (OS) was a secondary measure. In both, patients were matched with general population by age, sex, year, and race/ethnicity. Cure variations after LT were also adjusted for different waiting-list drop-outs. RESULTS: Considering DFS, the cure fraction after LT was 74.1% and after HR was 24.1% (effect size >0.8). LT outperformed HR within all transplant criteria considered (effect size >0.8), especially for multiple tumors (>0.9) and even in presence of a drop-out up to 20% (>0.5). Considering OS, the cure fraction after LT marginally increased to 75.8%, and after that HR increased to 40.5%. The effect size of LT over HR in terms of cure decreased for oligonodular tumors (<0.5), became small for drop-out up to ∼20% (<0.2), and negligible for single tumors <5 cm (∼0.1). CONCLUSION: As other malignancies, statistical cure can occur for HCC, primarily with LT and secondarily with HR, depending on waiting-list capabilities and efficacy of tumor recurrence therapies after resection.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
不良帅完成签到,获得积分10
刚刚
情怀应助shi采纳,获得10
1秒前
molihuakai应助shi采纳,获得10
1秒前
懒羊羊完成签到,获得积分10
1秒前
1秒前
鲤鱼一一完成签到,获得积分10
1秒前
完美世界应助小白白采纳,获得10
2秒前
慕青应助bubu采纳,获得10
3秒前
大力的冰蓝完成签到,获得积分10
3秒前
科研通AI6.3应助MAIDANG采纳,获得10
6秒前
6秒前
harrintong发布了新的文献求助10
6秒前
zzjjww发布了新的文献求助10
7秒前
8秒前
嘻嘻嘻完成签到,获得积分20
8秒前
Mocha发布了新的文献求助10
9秒前
万能图书馆应助yeuic采纳,获得30
11秒前
Nikki发布了新的文献求助10
11秒前
好晒完成签到,获得积分10
11秒前
FANG发布了新的文献求助10
11秒前
XuanLi发布了新的文献求助10
11秒前
bkagyin应助等待听安采纳,获得10
11秒前
夏天发布了新的文献求助10
11秒前
11完成签到,获得积分10
12秒前
脑洞疼应助科研通管家采纳,获得10
12秒前
桐桐应助科研通管家采纳,获得10
12秒前
斯文败类应助科研通管家采纳,获得10
12秒前
12秒前
13秒前
深情安青应助科研通管家采纳,获得10
13秒前
搜集达人应助科研通管家采纳,获得10
13秒前
13秒前
Moonpie应助科研通管家采纳,获得10
13秒前
Orange应助科研通管家采纳,获得10
13秒前
13秒前
打打应助科研通管家采纳,获得10
13秒前
13秒前
13秒前
酷波er应助科研通管家采纳,获得10
14秒前
14秒前
高分求助中
Principles of Economics, 11th Edition 10000
Prescott's Microbiology: 2026 Release ISE 10000
University Physics with Modern Physics, 16th edition 10000
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Environmental Leverage in Times of Climate Crisis: Product Standards, Carbon Border Measures and Preferential Trade Agreements 1000
Interactions of Vowel Quality and Prosody in East Slavic 1000
Erwählung und Berufung bei Paulus: Bedeutung, Entwicklung und Funktion einer Vorstellung in ihrem frühjüdischen und griechisch-römischen Kontext 850
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 内科学 物理 复合材料 催化作用 细胞生物学 无机化学 光电子学 物理化学 电极 基因
热门帖子
关注 科研通微信公众号,转发送积分 7192923
求助须知:如何正确求助?哪些是违规求助? 8829247
关于积分的说明 18641192
捐赠科研通 6828661
什么是DOI,文献DOI怎么找? 3175927
关于科研通互助平台的介绍 2328008
邀请新用户注册赠送积分活动 2150409